Although improvement of services would be expected over the years, long-term outcomes of intravitreal injections have not changed over the past decade and are suboptimal, according to a big data analysis performed in the U.K.
“This is not a U.K.-specific problem,” Roy Schwartz, MD, said at the virtual Association for Research in Vision and Ophthalmology meeting. Similar studies performed in other countries, including the U.S., show a similar pattern of visual gain in the first year followed by decline thereafter.
The U.K. study was aimed at describing changes in treatment outcomes